Analysis of endocrinological examination and lymphocyte composition of the peripheral blood in patients taking anamoreli
Not Applicable
- Conditions
- Patients with cancer cachexia
- Registration Number
- JPRN-UMIN000044653
- Lead Sponsor
- Okayama University
- Brief Summary
At week 3, anamorelin administration resulted in body weight gain and increased the levels of growth hormone and HbA1c, as well as insulin-like growth factor-1 standard deviation scores (IGF-1 SD scores). At the same time, negative correlations were observed between deltaIGF-1 SD score and deltathyroidstimulating hormone (TSH) and between deltaIGF-1 SD score and deltafree testosterone. deltaBody weight and deltaIGF-1 SD score correlated positively at week 12.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 13
Inclusion Criteria
Not provided
Exclusion Criteria
Women who are pregnant
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method